Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess
An eight-observation FDA Form 483 at Catalent Indiana’s Bloomington sterile injectable facility documents that a mammalian-hair contamination issue underlying a November 2025 Warning Letter has continued into 2026.